Short answer: As of November 15, 2026, no placebo-controlled trial of injected BPC-157 has reported results. A phase 2 trial (NCT07437547), first posted on ClinicalTrials.gov on February 27, 2026, is recruiting 120 adults with an MRI-confirmed grade II hamstring strain in Shenzhen, China, and compares 14 days of daily BPC-157 injections under the skin with placebo; its estimated primary completion date is February 14, 2027. A second placebo-controlled pilot, after rotator cuff surgery (NCT07803250), was posted on September 3, 2026 and is not yet recruiting. BPC-157 is a research peptide, not approved for human use, and this page gives no dosing.
BPC-157 is one of the most talked-about peptides for injuries, and until 2026 no placebo-controlled trial of it in an injury was registered on ClinicalTrials.gov. That changed in February. We read the trial records on ClinicalTrials.gov, FDA's July 2026 review, and the newest reviews on PubMed on November 15, 2026. Here is what each one says, with the type of evidence labelled.
The hamstring trial
The trial is called BPC-HAMSTR. Its sponsor is Hudson Biotech, and it runs at one site, Peking University Shenzhen Hospital. Here is what the ClinicalTrials.gov record says.
| Item | What the record says |
|---|---|
| Design | Phase 2, randomized 1:1, double-blind (participants, clinicians, investigators and outcome assessors), placebo-controlled |
| Who | 120 adults aged 18 to 45 (estimated) with an MRI-confirmed grade II hamstring strain that started within 72 hours of screening |
| Treatment | BPC-157 or matching placebo, injected under the skin by study staff once a day for 14 days, plus the same supervised rehab for everyone |
| Main results it will measure | Days until a return to unrestricted sport (over 8 weeks), and the change in injury size on MRI at day 14, read by blinded radiologists |
| Other results | Pain during activity, hamstring strength side-to-side, and a leg function score, all at day 56 |
| Dates | Started February 2, 2026; first posted February 27, 2026; estimated primary completion February 14, 2027; estimated study completion February 17, 2028 |
| Status | Recruiting. No results posted. |
A few details matter when you read it. The record does not list how much BPC-157 is given. It excludes people in formal anti-doping testing programs, and it has an independent safety monitoring committee. The record's arm list is untidy: both arms name both the drug and the placebo, and the placebo arm is labelled "experimental", although the description is clear that people get one or the other.
Hudson Biotech also sponsors a phase 2a trial of MOTS-c and a trial of a GHK-Cu skin gel at the same hospital. All three list the same start date, February 2, 2026.
The rotator cuff trial
The second placebo-controlled study, NCT07803250, comes from the University of Arkansas for Medical Sciences in Little Rock. It is a phase 1 pilot in adults having arthroscopic surgery for a full-thickness rotator cuff tear.
- People inject BPC-157 or saline under the skin themselves, once a day for 90 days after surgery.
- The main result is shoulder strength, measured by a blinded assessor at baseline, 12 weeks and 5 months. The plan also lists MRI tendon healing, questionnaires, range of motion and blood markers.
- The record lists 30 people (estimated), while its summary says 20. It describes the control group as saline injections in one place and as "no treatment" in another.
- Estimated start January 1, 2027; estimated completion August 1, 2027. Not yet recruiting.
The record itself says BPC-157 "has not yet been studied in formal human clinical trials" and is not approved by FDA.
Other registered studies
Two more BPC-157 records exist on ClinicalTrials.gov. Neither has posted results.
- NCT02637284: a placebo-controlled phase 1 study of BPC-157 tablets by mouth in 42 healthy volunteers in Tijuana, Mexico, registered in December 2015. Its status is "unknown", last verified October 2015. FDA's 2026 review says it could not find any results or a published paper.
- NCT07752381: a single-group study of a BPC-157 gummy supplement in 40 active adults, run by the company that sells it. It has no placebo group. It finished in November 2025 and was posted in August 2026.
What human evidence exists today
Human evidence. It is thin, and the newest reviews agree.
- A systematic review published October 8, 2026 searched up to June 1, 2026 and found three studies with 30 people in total: knee injections (16 people), bladder instillations (12) and an intravenous safety pilot (2). All were judged poor quality, and the overall certainty of evidence was "very low".
- An October 27, 2026 review in the Journal of the American Academy of Orthopaedic Surgeons found human musculoskeletal evidence "limited to one small retrospective uncontrolled case series" and said routine clinical use "cannot be currently recommended".
- FDA's July 2026 briefing document found five clinical studies. No serious adverse events appear to have been reported, but FDA wrote that the studies were short, small and gave limited safety information. It found no human data on how BPC-157 is absorbed or cleared after injection under the skin, by mouth, in the nose or through the skin.
Our BPC-157 human evidence page walks through each of those small studies.
What animal studies show
Animal evidence. The hamstring trial exists because of rat studies, which are many and mostly positive.
- In a 2021 rat study, cutting the quadriceps tendon from its muscle left a defect that did not heal on its own; rats given BPC-157 healed it, by the authors' measures.
- In a July 2026 rat study of Achilles tendon repair, BPC-157 scored better than controls but not by a statistically clear margin on the total scores, while TB-500 showed a clear strength gain. Giving both did not add anything.
Rat results often do not carry over to people. That gap is exactly what a placebo-controlled trial is built to test.
What FDA said in July 2026
FDA's briefing document for its Pharmacy Compounding Advisory Committee concluded that the balance of criteria "weighs against" adding BPC-157 to the 503A bulks list. It named a possible risk of immune reactions to an injected 15-amino-acid peptide and said the raw ingredient was not well characterized. FDA searched ClinicalTrials.gov on December 3, 2025, before the hamstring trial was registered, so its review does not mention it.
For what has happened since, including the October 2026 HHS draft policy, see our HHS compounding policy breakdown and FDA's 2026 peptide decisions.
What this means for you
For now, BPC-157 for injuries is "promising in rats, untested against placebo in people". The hamstring trial is the first real test, and its main results are not expected before its estimated primary completion date in February 2027. If you are thinking about BPC-157, talk to your clinician first, and treat any dose you read about as research information, not a plan. Our BPC-157 compound page tracks the research status.
Frequently asked questions
Is there a placebo-controlled trial of BPC-157?+
When will the BPC-157 hamstring trial results come out?+
What does the BPC-157 hamstring trial measure?+
How much human evidence is there for BPC-157?+
Is BPC-157 FDA approved?+
Related reading
- BPC-157 in humans: what the evidence shows
- BPC-157 compound page
- HHS six-peptide compounding policy (2026)
- TB-500 and thymosin beta-4: the human evidence
- BPC-157 vs GHK-Cu
- What "research use only" means
- How to track a peptide stack
Questions about the app? See the help center or join the Dose Track community.
Sources
Every fact in this article comes from one of these sources, checked on November 15, 2026. BPC-157 is a research peptide, not approved for human use. This article is for education. It is not medical advice, and nothing here is a dose recommendation.
- ClinicalTrials.gov. NCT07437547: BPC 157 for Acute Hamstring Muscle Strain Repair (BPC-HAMSTR). First posted February 27, 2026. clinicaltrials.gov
- ClinicalTrials.gov. NCT07803250: Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery. First posted September 3, 2026. clinicaltrials.gov
- ClinicalTrials.gov. NCT02637284: PCO-02 Safety and Pharmacokinetics Trial. clinicaltrials.gov
- ClinicalTrials.gov. NCT07752381: A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery. clinicaltrials.gov
- U.S. Food and Drug Administration. FDA Briefing Document, BPC-157-related bulk drug substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026. fda.gov/media/193343/download
- Poolton JT, et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026. PMID 42885452. PubMed
- Tham A, et al. Investigational peptides in orthopaedic practice: BPC-157, thymosin beta-4, and TB-500. J Am Acad Orthop Surg. 2026. PMID 42937313. PubMed
- Japjec M, et al. Stable gastric pentadecapeptide BPC 157 as a therapy for the disable myotendinous junctions in rats. Biomedicines. 2021. PMID 34829776. PubMed
- Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats. Jt Dis Relat Surg. 2026. PMID 42542926. PubMed